Differences of EDR Chemoresistance Assay and Prognosis between Recurrent Micropapillary Serous Ovarian Carcinoma and Serous Ovarian Carcinoma.
- Author:
Moon Seok CHA
1
Author Information
1. Department of Gynecology and Obstetrics, College of Medicine, Dong-A University, Busan, Korea. mscha@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Micropapillary serous ovarian cancer (MPSC);
Serous ovarian carcinoma;
Extreme drug resistance assay (EDR);
Prognosis
- MeSH:
Cisplatin;
Drug Resistance;
Etoposide;
Follow-Up Studies;
Ovarian Neoplasms;
Paclitaxel;
Prognosis*;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Obstetrics and Gynecology
2006;49(8):1655-1659
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this study was to identify chemoresistance and prognosis differences between recurrent micropapillary serous ovarian carcinoma (MPSC) and serous ovarian carcinoma. METHODS: The Extreme drug resistance (EDR) assay was performed in 13 recurrent micropapillary serous ovarian carcinoma and 56 recurrent serous ovarian carcinoma. RESULTS: Mean age of MPSC and Serous ovarian cancer were 41.1 and 58.0 respectively (p<0.05). Etoposide and Doxil were the two least resistance chemotherapeutic agents to recurrent MPSC but the most resistance agents to recurrent serous ovarian cancer. Taxol and cisplatin were the two most resistance agents to MPSC. The mean follow up was 42 months (range 1-173) The five-year overall survival rate of MPSC and serous ovarian carcinoma were 71.6% and 33.9% respectively. The mean survival were 136 months in MPSC compared with 72 months in serous ovarian carcinoma (p<0.035). CONCLUSION: In this retrospective analysis, MPSC showed very different in EDR results and favorable prognosis compare to serous ovarian carcinoma.
